[go: up one dir, main page]

MX2021011943A - Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial. - Google Patents

Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.

Info

Publication number
MX2021011943A
MX2021011943A MX2021011943A MX2021011943A MX2021011943A MX 2021011943 A MX2021011943 A MX 2021011943A MX 2021011943 A MX2021011943 A MX 2021011943A MX 2021011943 A MX2021011943 A MX 2021011943A MX 2021011943 A MX2021011943 A MX 2021011943A
Authority
MX
Mexico
Prior art keywords
treatment
urothelial carcinoma
tyrosine kinase
kinase inhibitors
fgfr
Prior art date
Application number
MX2021011943A
Other languages
English (en)
Inventor
Porre Peter Marie Z De
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2021011943A publication Critical patent/MX2021011943A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen métodos de tratamiento de carcinoma urotelial con una especialidad farmacéutica aprobada que contiene un inhibidor del receptor de factor de crecimiento de fibroblastos (FGFR); también se describen métodos de venta u oferta para la venta de una especialidad farmacéutica que contiene un inhibidor de receptor de factor de crecimiento de fibroblastos (FGFR).
MX2021011943A 2019-03-29 2020-03-27 Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial. MX2021011943A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19166429 2019-03-29
US201962833395P 2019-04-12 2019-04-12
PCT/EP2020/058814 WO2020201138A1 (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Publications (1)

Publication Number Publication Date
MX2021011943A true MX2021011943A (es) 2021-11-03

Family

ID=69954076

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011943A MX2021011943A (es) 2019-03-29 2020-03-27 Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.

Country Status (15)

Country Link
US (1) US20220175768A1 (es)
EP (2) EP4548935A2 (es)
JP (1) JP2022527482A (es)
KR (1) KR20210143878A (es)
CN (1) CN113645975A (es)
AU (1) AU2020253054A1 (es)
BR (1) BR112021019203A2 (es)
CA (1) CA3130773A1 (es)
IL (1) IL286727A (es)
JO (1) JOP20210260A1 (es)
MA (1) MA55486A (es)
MX (1) MX2021011943A (es)
PH (1) PH12021552352A1 (es)
SG (1) SG11202109854RA (es)
WO (1) WO2020201138A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024004488A (es) 2021-10-12 2024-07-10 Taris Biomedical Llc Formulaciones y sistemas de erdafitinib para administración intravesical.
KR20240145513A (ko) 2022-02-18 2024-10-07 타리스 바이오메디컬 엘엘씨 에르다피티닙 제형 및 방광내 투여를 위한 삼투성 시스템
CN116106240A (zh) * 2022-12-26 2023-05-12 华中农业大学 一种尿液酪氨酸检测体系、检测方法及检测试剂盒
WO2024173377A1 (en) 2023-02-13 2024-08-22 Taris Biomedical Llc Erdafitinib for intravesical administration for use in the treatment of bladder cancer
WO2024173716A1 (en) 2023-02-17 2024-08-22 Taris Biomedical Llc Erdafitinib for intravesical administration for use in the treatment of bladder cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CA2609353C (en) 2005-05-23 2015-04-28 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
MX392774B (es) 2014-09-26 2025-03-24 Janssen Pharmaceutica Nv Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderán al tratamiento con un inhibidor fgfr
TWI798199B (zh) * 2017-02-06 2023-04-11 比利時商健生藥品公司 癌症治療
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان

Also Published As

Publication number Publication date
JP2022527482A (ja) 2022-06-02
SG11202109854RA (en) 2021-10-28
WO2020201138A1 (en) 2020-10-08
EP3946340A1 (en) 2022-02-09
KR20210143878A (ko) 2021-11-29
EP4548935A2 (en) 2025-05-07
US20220175768A1 (en) 2022-06-09
MA55486A (fr) 2022-02-09
BR112021019203A2 (pt) 2021-11-30
JOP20210260A1 (ar) 2023-01-30
IL286727A (en) 2021-10-31
PH12021552352A1 (en) 2022-09-05
CN113645975A (zh) 2021-11-12
AU2020253054A1 (en) 2021-09-30
CA3130773A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
MX2021011943A (es) Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.
MX2020011868A (es) Inhibidores de los receptores erbb.
UY38837A (es) Proceso de elaboración de moduladores de cftr
MX2021014455A (es) Inhibidores de proteina cinasas dependientes de adn.
BR112017007769A2 (pt) compostos e composições para modulação de atividades de cinase de egfr mutante
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EP4003993A4 (en) Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
EA201691916A1 (ru) Биарильные ингибиторы киназы
UY35798A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
MX2018004892A (es) Compuestos de 2-piridazin-3(2h)-ona 2-aril sustituidas y 2-heteroaril sustituidas como inhibidores de las tirosina quinasas fgfr.
CY1121444T1 (el) Παραγωγα κιnoλonης ως αναστoλεις υποδοχεα αυξητικου παραγοντα ινοβλαστων
NZ744554A (en) Bruton’s tyrosine kinase inhibitors
MX2017013797A (es) Inhibidor de janus quinasa.
MX2020007947A (es) Inhibidores de erbb/btk.
CL2014000887A1 (es) Compuestos derivados de 1-fenil-imidazol condensado y sus sales, inhibidores de proteinas quinasas; composicion farmaceutica que los comprende; y su uso para el tratamiento de una condicion donde se desea la inhibicion de la quinasa del fgfr tal como cancer.
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2019001337A1 (es) Formulaciones farmacéuticas.
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
MX2019010642A (es) Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos.
CL2019000573A1 (es) Composiciones para comprimidos.
MX2019014845A (es) Compuestos de aminotiazol como inhibidores de la proteina quinasa.
EP3986411A4 (en) SMALL MOLECULE TYROSINE KINASE SRC INHIBITORS
BR112022002222A2 (pt) Derivados de quinolina como inibidores de proteínas quinases
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака